FogPharma and ARTBIO Announce Collaboration to Co-Develop Multiple Helicon™-Enabled Alpha-Particle Radioligand Therapies for the Treatment of Cancer May 21, 2024
Aulos Bioscience Enters Into Clinical Trial Collaboration and Supply Agreement With Merck To Study Combination of Bavencio® With AU-007 May 21, 2024
Phanes Therapeutics Announces Clinical Supply Agreement with Roche to Evaluate PT217 in Combination with an anti-PD-L1 Therapy May 15, 2024
CytomX Therapeutics Announces Clinical Collaboration with Merck to Evaluate CX-801 in Combination with KEYTRUDA May 15, 2024
Oregon Therapeutics & Lantern Pharma Launch Strategic AI Collaboration to Optimize Development of XCE853 May 14, 2024
Kite and Arcellx share design of global Ph 3 trial, iMMagine-3, to evaluate anito-cel in patients exposed to both an lMiD drug and an anti-CD38 mAb May 14, 2024
Intensity Therapeutics and The Swiss Group for Clinical Cancer Research SAKK to Conduct a Ph 2 Randomized Trial in Early-Stage Breast Cancer in Europe for INT230-6 May 14, 2024
Siren Biotechnology and Catalent Enter Partnership for Manufacturing of AAV Gene Therapies for Cancer May 14, 2024
TC BioPharm Announces Execution of Second Non-Binding Letter of Intent for Acquisition, Targeting Innovative CAR-T Therapies May 14, 2024
Mariana Oncology to be Acquired by Novartis to Advance Precision Radiopharmaceuticals to Treat Cancer May 7, 2024
Astellas and Poseida Therapeutics Enter Into Research Collaboration and License Agreement to Develop Novel Allogeneic Cell Therapies in Oncology May 7, 2024
G1 Therapeutics and Pepper Bio Announce Global (Excluding Asia-Pac) License Agreement for Lerociclib May 7, 2024
Delphia Therapeutics Launches to Pioneer a New Field of Cancer Medicines based on Activation Lethality platform May 7, 2024
BridgeBio launches BridgeBio Oncology Therapeutics (BBOT) with $200M of private external capital to accelerate the development of its novel precision oncology pipeline May 7, 2024
Tharimmune Announces Option Agreement for Key Technologies for Generating HER2/HER3 Antibody Drug Conjugates (ADCs) May 1, 2024
Hanmi Enters into Clinical Trial Collaboration and Supply Agreement with MSD to Evaluate BH3120 + KEYTRUDA May 1, 2024
Flindr Therapeutics announces €20 million Series A financing to advance first-in-class small molecule inhibitors May 1, 2024
Endeavor BioMedicines Raises $132.5 Million Oversubscribed Series C Financing to Advance Pipeline of Transformational Medicines May 1, 2024
Ono Enters into a Collaboration Agreement with PRISM BioLab to Generate Novel Drug Candidates in the Oncology Area May 1, 2024
$15 million CIRM Grant Supports the Ongoing Ph 1 TRAVERSE Trial of ALLO-316 in Patients with Advanced or Metastatic RCC May 1, 2024
GV20 Therapeutics Announces Clinical Trial Collaboration to Evaluate GV20-0251 Against IGSF8, in Combination with KEYTRUDA April 23, 2024
Pathios Therapeutics Raises $25M in First Close of Series B Financing to Advance First-in-Class Immunotherapy Approach into Clinic April 23, 2024
